Although these findings collectively support sCD163 as a potential biomarker in SSc, it has to be considered that in a recent study such a soluble molecule did not emerge as a useful biomarker for specific SSc-related clinical manifestations [237]. The gene discussed is CD163; the disease is systemic sclerosis.